MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Chembio Diagnostics, Inc. (CEMI) Signs Two Agreements With RVR Diagnostics SDN BHD 0 comments
    Feb 12, 2014 5:31 PM | about stocks: CEMI

    Chembio Diagnostics announced today that it has entered into two agreements with RVR Diagnostics SDN BHD, a privately held company in Malaysia, where RVR will become a licensee, distributor, and contract manufacturer of Chembio products. The agreements are in line with Chembio's efforts to establish a market presence in Asia.

    According to the terms of the agreement, RVR will be granted exclusive distribution rights for certain countries in the region and will now be able to manufacture Chembio's DPP® HIV 1/2 Assay and DPP® HIV-Syphilis Assay. There is a possibility for RVR to manufacture other Chembio products that use patended DPP® technology in the future.

    Javan Esfandiari, Chembio's SVP of Research & Development, commented, "We look forward to collaborating with RVR on our patented DPP® technology to support our strategy of growth in Asia, as well as RVR's commitment to provide high quality point-of-care technology in the Asia market."

    The agreements consist of a technology transfer, license and distribution agreement, and also a contract manufacturing agreement. Under the License Agreement, the parties will collaborate so that manufacturing and distribution activities can begin in 2015. Chembio will receive a non-refundable signature fee for this work and a contingent fee after transfer activity milestones are met.

    As for the distribution part of this agreement, RVR will distribute the products in the markets under license from Chembio (subject to a royalty and continuing supply of reagents). RVR is required to manufacture the DPP® HIV 1/2 Assay product in accordance with Chembio's FDA-approved specifications.

    The Manufacturing Agreement enables Chembio to source products from RVR's facility for shipment to customers outside RVR's exclusive territory. Chembio will gain a new strategically located and cost-effective capacity that will be important in serving a number of global markets.

    RVR's President, Avijit Roy, remarked, "We look forward to an exciting and bright future with Chembio in serving the Asia market."

    For more information on Chembio and the agreements, please visit chembio.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CEMI
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.